A trial with XG005 met it's primary and secondary endpoints, demonstrating a statistically significant reduction in ...

A single-center retrospective study in China found a significant association between pain duration and intensity in patients ...

Background: Numerical rating scales (NRS), and verbal rating scales (VRS) showed to be reliable and valid tools for subjective cancer pain measurement, but no one of them consistently proved to be ...

A comprehensive lifestyle-improvement program -- delivered entirely online -- helped patients with inflammatory arthritis (IA ...

Vertex Pharmaceuticals' suzetrigine is an investigational pain treatment. Its first approved indication could come as early ...

Despite the real problems with the additional indication being sought for suzetrigine, this drop in the stock is still an ...

Patients also had a score of at least 40 on a 100-point visual analogue scale of pain. The primary endpoint was the mean pain score on an 11-point numerical pain rating scale, which was used to ...

Based on patients' responses to a numeric pain rating scale (NPRS) that ranges from 0 (no pain) to 10 (the worst possible pain), both patients in the placebo group and patients in the treatment ...

A Vertex drug hit its mark in a Phase 2 study in chronic pain, but faces questions about its performance versus placebo.

Vertex Pharmaceuticals announced results of a midstage trial of its non-opioid experimental painkiller in chronic back pain, ...

Vertex Pharmaceuticals' suzetrigine reduced pain in Phase 2 trials for lumbosacral radiculopathy. Plans for Phase 3 trials ...

Detailed price information for Vertex Pharmaceutic (VRTX-Q) from The Globe and Mail including charting and trades.